SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

Parmax Pharma

BSE: 540359 29 Jun 2025
Healthcare
₹ 38.02
Parmax Pharma Limited specializes in Pharmaceuticals within the Healthcare sector.

Parmax Pharma - Share Price & Details

Market Cap
₹14.5
High /Low
55.0 / 28.7
Stock P/E
NA
Book Value
₹-5.32
Dividend Yield
0.0
ROCE
-12.5
ROE
₹NA
Face Value
10.0
PEG Ratio
NA
EVEBITDA
₹73.6
Debt
7.70
CMP / FCF
-11.5
Debt to equity
₹84.4
NP Ann
-2.09
High price all time
81.9
Piotroski score
₹6.0
Graham Number
NA
No. Eq. Shares
0.37
Net CF
₹0.04
Net profit
-2.09
Price to book value
NA
Interest Coverage
₹-1.24
Low price all time
12.5
Industry PE
33.8
Reserves
₹-6.44
Free Cash Flow
₹-1.36

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
LOOKS HEALTH SERVICES LIMITEDNANANANA5.11256.0
Triochem Products Ltd.,NANANANA0
Parmax Pharma LimitedNANANANA14.5
Span Divergent LimitedNANANANA11.815.0
DECIPHER LABS LIMITEDNANANANA11.4

Peer Comparison Chart


About Parmax Pharma

Parmax Pharma Limited, with Security Code 540359, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Latest News

Is Parmax Pharma overvalued or undervalued?

(11 Jun 2025)
As of February 1, 2024, Parmax Pharma's valuation has downgraded to risky, with negative financial ratios indicating it is overvalued compared to peers like...
Read more →

Parmax Pharma Reports Strong Sales Growth Amid Ongoing Profitability Challenges in March 2025

(05 Jun 2025)
Parmax Pharma has reported its financial results for the quarter ending March 2025, showing a significant year-on-year increase in net sales...
Read more →

PARMAX PHARMA Share Price Today Down 8%

(12 May 2025)
Real-time updates on PARMAX PHARMA share price. Check out the detailed analysis of the company in this live blog.
Read more →

Parmax Pharma Reports Strong Sales Growth Amid Market Reevaluation in February 2025

(17 Feb 2025)
Parmax Pharma announced its financial results for the quarter ending December 2024, revealing net sales of Rs 15.56 crore, marking a year-on-year growth of 188...
Read more →

Q3 Results: RVNL, EaseMyTrip, MTNL, Aditya Birla Fashion And Others To Announce Earnings Today; Full List Here

(14 Feb 2025)
GlaxoSmithKline Pharmaceuticals, Dilip Buildcon, RateGain Travel Technologies and Dish TV will also declare their financial results for the...
Read more →

Parmax Pharma Standalone September 2024 Net Sales at Rs 9.28 crore, up 128.05% Y-o-Y

(25 Nov 2024)
Sep'24, Jun'24, Sep'23. Net Sales/Income from operations, 9.28, 7.82, 4.07. Other Operating Income, --, --, --. Total Income From Operations...
Read more →